Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Across these trials, 1.35% (279 of 20,598) of participants who received a GLP-1 RA had ≥1 episode of AFib reported as a serious adverse event, compared with 1.37% (282 of 20,608) of those who ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

There was a 132.6 percent increase in patients prescribed GLP-1 RAs between the last six months of 2022 and the last six months of 2023 (1.89 versus 4.41 patients per 1,000 patients).

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...